<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Urogen Pharma Ltd — News on 6ix</title>
<link>https://6ix.com/company/urogen-pharma-ltd</link>
<description>Latest news and press releases for Urogen Pharma Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/urogen-pharma-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cfcf78dffbe2df11f043.webp</url>
<title>Urogen Pharma Ltd</title>
<link>https://6ix.com/company/urogen-pharma-ltd</link>
</image>
<item>
<title>UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-launches-lg-utuc-luminaries-initiative-recognizing-excellence-and-leadership-in-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing</description>
</item>
<item>
<title>Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/journal-of-urology-publishes-envision-trial-results-showing-722percent-24-month-duration-of-response-with-zusduri</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/journal-of-urology-publishes-envision-trial-results-showing-722percent-24-month-duration-of-response-with-zusduri</guid>
<pubDate>Mon, 30 Mar 2026 12:00:00 GMT</pubDate>
<description>72.2% Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months (79.6%) PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the publication of results from the pivotal Phase 3 ENVISION trial of ZUSDURI™ (mitomycin) for intravesical solution in The Journal</description>
</item>
<item>
<title>UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-applauds-bcans-new-faces-of-bladder-cancer-report-highlighting-recurrence-burden-and-fear-of-recurrence-106</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-applauds-bcans-new-faces-of-bladder-cancer-report-highlighting-recurrence-burden-and-fear-of-recurrence-106</guid>
<pubDate>Fri, 13 Mar 2026 12:00:00 GMT</pubDate>
<description>National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50Many respondents report undergoing five or more cystoscopies, with some experiencing more than 15 procedures PRINCETON, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a biotechnology company dedicated to developing innovative therapies for urothelial and specialty cancers, today commended the Bladder Cancer Advocacy Network (BCAN) on its rel</description>
</item>
<item>
<title>UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-announces-zusduritm-launch-is-on-track-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-announces-zusduritm-launch-is-on-track-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 02 Mar 2026 13:00:00 GMT</pubDate>
<description>Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 million, reflecting the initial launch period ahead of the permanent J CodePermanent J Code for ZUSDURI became effective on January 1, 2026, streamlining reimbursement procedures and supporting broader patient accessJELMYTO® achieved net product sales of $94 million in 2025, repr</description>
</item>
<item>
<title>UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-announces-refinanced-term-loan-agreement-with-pharmakon-advisors</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-announces-refinanced-term-loan-agreement-with-pharmakon-advisors</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded</description>
</item>
<item>
<title>ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/zusduritm-achieves-durable-complete-responses-across-eortc-risk-groups-in-patients-with-recurrent-lg-ir-nmibc</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/zusduritm-achieves-durable-complete-responses-across-eortc-risk-groups-in-patients-with-recurrent-lg-ir-nmibc</guid>
<pubDate>Fri, 27 Feb 2026 13:30:00 GMT</pubDate>
<description>• EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative, non-surgical therapies for urothelial and specialty cancers, today announced new post-hoc analyses from the Phase 3 ENVISION trial showing that ZUSDURI™ (mitom</description>
</item>
<item>
<title>UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
<description>PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the TD Cowen 46th Annual Health Care Conference to take place March 2-4, 2026. TD Cowen 46th Annual Health Care Conference Date / Time:March 3, 2026, at 1:50 PM ETFormat:Presentation and 1x1 investor meetingsLocation:Boston, MAWebcast Lin</description>
</item>
<item>
<title>UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-to-report-fourth-quarter-and-full-year-2025-financial-results-on-monday-march-2-2026</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-to-report-fourth-quarter-and-full-year-2025-financial-results-on-monday-march-2-2026</guid>
<pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
<description>Conference Call and Webcast Scheduled for Monday, March 2, 2026 at 10:00 AM ETPRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2025 financial results on Monday, March 2nd , 2026, prior to the open of the stock market. The announcement will be followed by a live audio we</description>
</item>
<item>
<title>UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-present-guggenheim-securities-emerging-outlook-biotech-summit-2026-02</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-present-guggenheim-securities-emerging-outlook-biotech-summit-2026-02</guid>
<pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative</description>
</item>
<item>
<title>Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/permanent-j-code-zusduritm-now-effect-expanding-patient-access-innovative-bladder</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/permanent-j-code-zusduritm-now-effect-expanding-patient-access-innovative-bladder</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative</description>
</item>
<item>
<title>UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12-05</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12-05</guid>
<pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative</description>
</item>
<item>
<title>UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-present-piper-sandler-37th-annual-healthcare-conference-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-present-piper-sandler-37th-annual-healthcare-conference-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative</description>
</item>
<item>
<title>UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-reports-third-quarter-2025-financial-results-zusduritm-launch-gains-momentum</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-reports-third-quarter-2025-financial-results-zusduritm-launch-gains-momentum</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan</description>
</item>
<item>
<title>UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-reports-778-three-month-complete-response-rate-phase-3-utopia-trial-ugn-103</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-reports-778-three-month-complete-response-rate-phase-3-utopia-trial-ugn-103</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative</description>
</item>
<item>
<title>UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-present-guggenheim-securities-healthcare-innovation-conference-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-present-guggenheim-securities-healthcare-innovation-conference-2025-11</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative</description>
</item>
<item>
<title>UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-report-third-quarter-2025-financial-results-thursday-november-6th-2025</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-report-third-quarter-2025-financial-results-thursday-november-6th-2025</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.</description>
</item>
<item>
<title>Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/centers-medicare-and-medicaid-services-assigns-permanent-j-code-zusduritm-effective</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/centers-medicare-and-medicaid-services-assigns-permanent-j-code-zusduritm-effective</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative</description>
</item>
<item>
<title>ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/zusduritm-clinical-review-published-reviews-urologytm-highlights-durable-efficacy-and</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/zusduritm-clinical-review-published-reviews-urologytm-highlights-durable-efficacy-and</guid>
<pubDate>Thu, 02 Oct 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative</description>
</item>
<item>
<title>UroGen Pharma to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-present-upcoming-investor-conferences-2025-08-21</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-present-upcoming-investor-conferences-2025-08-21</guid>
<pubDate>Thu, 21 Aug 2025 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative</description>
</item>
<item>
<title>UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-expands-commercial-portfolio-launch-zusduritm-and-reports-second</link>
<guid isPermaLink="true">https://6ix.com/company/urogen-pharma-ltd/news/urogen-pharma-expands-commercial-portfolio-launch-zusduritm-and-reports-second</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent low-grade</description>
</item>
</channel>
</rss>